Related Experiment Videos
TNP-470 is an effective antimicrosporidial agent
C Coyle1, M Kent, H B Tanowitz
1Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
Abstract:
Therapy for microsporidia, which cause diarrhea and a wasting syndrome in persons with AIDS, has had limited success. Fumagillin, a naturally secreted water-insoluble antibiotic, has in vitro activity against microsporidia and has been used successfully in the treatment of superficial keratitis in patients with AIDS, but systemic therapy has been limited by toxicity of the currently available fumagillin salt. TNP-470, a semisynthetic analogue of fumagillin, was studied in vitro and in the athymic nude mouse model of microsporidiosis. RK13 cells were infected with microsporidia of the family Encephalitozoonidae and treated at day 3 with TNP-470. This agent was highly effective, with an ID50 (50% inhibitory dose compared with control) of 0.001 microg/mL. TNP-470 also demonstrated in vivo activity against Encephalitozoon cuniculi, with prolonged survival and the prevention of the development of ascites in infected athymic mice. These data suggest that the fumagillin derivative TNP-470 is a promising agent for the treatment of microsporidiosis.
Insights
TNP-470, a fumagillin derivative, shows high effectiveness against microsporidia in vitro and in vivo. This promising agent could offer a new treatment for microsporidiosis, a condition causing diarrhea and wasting in AIDS patients.
Area of Science:
- Microbiology
- Parasitology
- Infectious Diseases
Background:
- Microsporidiosis causes significant health issues, particularly diarrhea and wasting syndrome in individuals with Acquired Immunodeficiency Syndrome (AIDS).
- Current therapeutic options for microsporidiosis are limited, with systemic treatment hampered by the toxicity of existing fumagillin salts.
- Fumagillin exhibits in vitro activity against microsporidia and has shown success in treating superficial keratitis in AIDS patients.
Purpose of the Study:
- To evaluate the efficacy of TNP-470, a novel fumagillin analogue, against microsporidia.
- To assess the in vitro and in vivo activity of TNP-470 in a relevant model of microsporidiosis.
Main Methods:
- In vitro studies involved infecting RK13 cells with microsporidia (family Encephalitozoonidae) and treating with TNP-470.
- In vivo studies utilized the athymic nude mouse model infected with Encephalitozoon cuniculi.
- Efficacy was determined by calculating the 50% inhibitory dose (ID50) in vitro and observing survival rates and ascites development in vivo.
Main Results:
- TNP-470 demonstrated potent in vitro activity with a 50% inhibitory dose (ID50) of 0.001 microg/mL.
- In vivo, TNP-470 significantly prolonged survival in infected athymic mice.
- The agent effectively prevented the development of ascites in mice infected with Encephalitozoon cuniculi.
Conclusions:
- TNP-470 exhibits significant in vitro and in vivo efficacy against microsporidia.
- This fumagillin derivative represents a promising therapeutic candidate for treating microsporidiosis.
- Further investigation into TNP-470 could lead to improved systemic treatment options for this opportunistic infection.